A three-day National Tuberculosis Academic Conference was held in Xiamen Xiangyu International Hotel on May 25, 2017. "TB control, inheritance and innovation"-is the theme of this conference. The conference was jointly organized by the Tuberculosis and China Centers for Disease Control and Prevention Tuberculosis Prevention and Treatment Clinical Center, the National Tuberculosis Hospital Alliance, and the Beijing Tuberculosis Diagnosis and Treatment Technology Innovation Alliance. More than 2,000 Chinese and foreign scholars and guests will attend the conference. In addition to the main venue of this conference, many branch venues conducted multi-faceted and multi-level academic exchanges around the latest developments in anti-tuberculosis. This year coincides with the 80th anniversary of the founding of the Tuberculosis Branch of the Chinese Medical Association, and the commemorative event will be held grandly.
In order to promote products and promote academic exchanges, the staff of Shenyang Hongqi Pharmaceutical Co., Ltd. arrived at the venue early to set up the booth, prepare materials and publicize the exhibition stand, and greet and visit the experts. The marketing department of the company contacted the conference affairs team in advance to publicize the situation of Hongqi Pharmaceutical Company, the "Young Eagle" project, and the products of the Hongqi Pharmaceutical product rifampicin II capsules in the conference materials essays. Everyone is looking forward to gaining something at the National Tuberculosis Academic Conference.
This conference also attracted many domestic production and sales enterprises in the field of anti-tuberculosis and tuberculosis diagnosis. Hongqi Pharmaceuticals is even more meticulously prepared. The "Young Eagle" project jointly launched with the Beijing Tuberculosis Diagnosis and Treatment Technology Innovation Alliance held a grand signing ceremony at 13:30 on the 25th. This project is the first to celebrate the 80th anniversary of the establishment of the Tuberculosis Branch. The project aimed at cultivating reserve talents for tuberculosis will help outstanding domestic young and middle-aged experts to participate in domestic and international academic exchanges and learning. This is the corporate responsibility and social responsibility of Hongqi Pharmaceutical.
I wish this National Tuberculosis Academic Conference a complete success, and Hongqi Pharmaceutical will bring more detailed reports.
The "Young Eagle" project was jointly initiated by Shenyang Hongqi Pharmaceutical Co., Ltd., a member company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Beijing Tuberculosis Diagnosis and Treatment Technology Innovation Alliance. It aims to select and fund young and middle-aged domestic anti-tuberculosis experts under the age of 45 to participate in the international , Domestic academic exchanges and learning, improve the level of diagnosis and treatment, and better realize the strategy of tuberculosis prevention and treatment during the 13th Five-Year Plan. The first phase of this project is five years, Hongqi Pharmaceuticals invests 300,000 yuan per year, and Innovation Alliance invests 100,000 yuan as the basic fund. This project welcomes more enterprises and individuals to participate. For this reason, the Innovation Alliance has strict rules and regulations for the use of selection, supervision, management and assessment fees.